Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.1281
+0.0055 (4.49%)
Aug 28, 2026, 11:43 AM EDT - Market open
Valion Bio Employees
Valion Bio had 52 employees as of December 31, 2025. The number of employees increased by 45 or 642.86% compared to the previous year.
Employees
52
Change (1Y)
45
Growth (1Y)
642.86%
Revenue / Employee
n/a
Profits / Employee
-$369,808
Market Cap
2.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 52 | 45 | 642.86% |
| Dec 31, 2024 | 7 | -2 | -22.22% |
| Dec 31, 2023 | 9 | -7 | -43.75% |
| Jun 30, 2023 | 11 | - | - |
| Dec 31, 2022 | 16 | 9 | 128.57% |
| Dec 31, 2021 | 7 | -1 | -12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Calidi Biotherapeutics | 29 |
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Silexion Therapeutics | 14 |
| Genprex | 13 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| Oragenics | 3 |
VBIO News
- 1 day ago - Valion Bio announces 1-for-25 reverse stock split - TheFly
- 1 day ago - Valion Bio Announces Reverse Stock Split - Accesswire
- 11 days ago - Valion Bio announces U.S. government-funded entolimod studies - TheFly
- 11 days ago - Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier - TheFly
- 13 days ago - Valion Bio Quarterly report: Q2 2026 - Filings
- 13 days ago - Valion Bio Transcript: EGM 2026 - Transcripts
- 15 days ago - Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase - Accesswire
- 16 days ago - Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury - Accesswire